T**********e
发帖数: 29576 | 1 受够了药业供应链被烙印tg控制，老头自己开药厂。
Trump to Tap New Company to Make Covid-19 Drugs in the U.S.
The Trump administration will announce on Tuesday that it has signed a $354
million four-year contract with a new company in Richmond, Va., to
manufacture generic medicines and pharmaceutical ingredients that are needed
to treat Covid-19 but are now made overseas, mostly in India and China.
The contract, awarded to Phlow Corp. by the Biomedical Advanced Research and
Development Authority, meshes President Trump’s “America First” economic
promises with concerns that coronavirus treatments be manufactured in the
United States. It may be extended for a total of $812 million over 10 years,
making it one of the largest awards in the authority’s history.
“This is an historic turning point in America’s efforts to onshore its
pharmaceutical production and supply chains,” Peter Navarro, Mr. Trump’s
trade adviser, whose White House portfolio includes the global supply chain,
said in a brief interview on Monday evening. The project, he said, “will
not only help bring our essential medicines home but actually do so in a way
that is cost competitive with the sweatshops and pollution havens of the
world.”
It was unclear why the administration decided to award such a large contract
to a new company when an entire industry exists — known as contract
manufacturing — that makes drugs for other companies. However,
manufacturers that operate in the United States generally make finished
products using raw ingredients imported from elsewhere. They do not make the
raw ingredients.
And Phlow markets itself in boldly nationalist terms. “The United States’
drug supply chain is broken,” its website declares, “becoming dangerously
dependent upon foreign suppliers for our most essential generic medicines.”
In an interview, Dr. Eric Edwards, the chief executive and president of
Phlow, described the company as a “public benefit corporation” that was
dedicated to having a social impact, and he said his firm also intended to
create “the nation’s first strategic active pharmaceutical ingredient
reserve” — in essence, a stockpile for pharmaceutical ingredients to be
used in the event of drug shortages or an emergency.
“There are not a lot of people wanting to bring back generic medicine
manufacturing to the United States that has been lost to India and China
over decades,” said Dr. Edwards, who described himself as a serial
entrepreneur as well as a physician. “You need someone like the federal
government saying this is too important for us not to focus on.”
In a statement that the Trump administration plans to release Tuesday
morning, Mr. Trump’s health secretary, Alex M. Azar II, called the
initiative “a significant step to rebuild our domestic ability to protect
ourselves from health threats.”
Phlow will lead a team of private sector entities that includes Civica Rx, a
nonprofit created in 2018 by American hospitals to alleviate drug shortages
; Ampac Fine Chemicals, a custom manufacturer of pharmaceutical ingredients;
and the Medicines for All Institute, a nonprofit arm of the Virginia
Commonwealth University’s College of Engineering that also receives funding
from the Bill and Melinda Gates Foundation. Dr. Frank Gupton, the founder
and chief executive of Medicines for All, sits on Phlow’s board.
Martin van Trieste, the chief executive of Civica Rx, is also on Phlow’s
board. And another board member, Rosemary Gibson, is a senior adviser at the
Hastings Center, a nonpartisan bioethics institute, who has frequently
written and testified about the dangers of the United States’ reliance on
Chinese drug manufacturing.
Dr. Edwards said his company would focus on “critical care medicines used
to treat hospitalized patients with Covid-19,” including “medicines that
are used for sedation to help patients requiring ventilator support, pain
management and certain essential antibiotics.” Production has already begun
at an Ampac facility, he said, while Phlow builds new plants.
China is the main global supplier of the raw ingredients used in many common
drugs, including antibiotics like penicillin and painkillers like ibuprofen
and aspirin.
In recent years, observers like Ms. Gibson have warned about dependence on
China for raw pharmaceutical ingredients, pointing to the widespread recalls
in 2018 of the blood pressure drug valsartan that were traced to problems
at a single Chinese factory that made the drug’s active ingredient, which
was contaminated with a possible carcinogen.
Dr. Edwards said Phlow was incorporated in January, though he began working
on it last year, before the emergence of the coronavirus. The aim, he said,
was “strengthening America’s supply chain and manufacturing American
generic medicines at risk of shortage.” He planned at first to use advanced
manufacturing technology to produce generic drugs for children. But he
switched gears, he said, when the pandemic emerged, and responded to a
request from the Biomedical Advanced Research and Development Authority for
proposals to use advanced manufacturing to assist in the Covid-19 response.
Dr. Edwards is also a founder of the pharmaceutical company Kaléo, which he
created along with his twin brother, Evan Edwards, to sell the Auvi-Q, a
competitor to the EpiPen, the emergency allergy treatment. The Auvi-Q, a
talking auto-injectable pen, hit the market in 2013 as part of a partnership
with the French pharmaceutical giant Sanofi, but Dr. Edwards’s company
soon ran into roadblocks.
In 2015, the Auvi-Q was recalled after it turned out the product might not
have been delivering the proper dosage of epinephrine, the medicine used to
stop a dangerous allergic reaction. In 2016, Sanofi ended its relationship
with Kaléo and returned the licensing rights. Kaléo relaunched the
improved Auvi-Q in 2017.
In 2016, Kaléo ran into a separate controversy with its other product,
Evzio, which was similar to the Auvi-Q but delivered an injection of
naloxone, which can stop a drug overdose. That year, Kaléo quintupled the
price of Evzio, prompting letters from members from Congress who wanted to
know why the company had raised the price in the middle of an opioid
epidemic. (The company said it did so to cover the cost of a patient
assistance program that lowered the out-of-pocket costs for people who could
not afford it.)
A spokesman for Phlow said Monday night that “Dr. Edwards departed Kaléo
on good terms over one year ago and had no oversight of drug pricing during
the end of his tenure.” | h**0
发帖数: 374 | 2 若是猪党在台上，肯定又是外包出去，把中产的工作也都外包掉
354
needed
and
economic
years,
【在 T**********e 的大作中提到】
: 受够了药业供应链被烙印tg控制，老头自己开药厂。
: Trump to Tap New Company to Make Covid-19 Drugs in the U.S.
: The Trump administration will announce on Tuesday that it has signed a $354
: million four-year contract with a new company in Richmond, Va., to
: manufacture generic medicines and pharmaceutical ingredients that are needed
: to treat Covid-19 but are now made overseas, mostly in India and China.
: The contract, awarded to Phlow Corp. by the Biomedical Advanced Research and
: Development Authority, meshes President Trump’s “America First” economic
: promises with concerns that coronavirus treatments be manufactured in the
: United States. It may be extended for a total of $812 million over 10 years,
| T**********e
发帖数: 29576 | 3
这公司也不好说，等老头下台了照样外包，烙印药原料又便宜又好。
【在 h**0 的大作中提到】
: 若是猪党在台上，肯定又是外包出去，把中产的工作也都外包掉
:
: 354
: needed
: and
: economic
: years,
| r*********t
发帖数: 4911 | 4 就看国民能否在4年内醒来。没醒过来，还相信和党和主党唱双簧，还去订阅这些左媒
，那么就会发生你说的。
【在 T**********e 的大作中提到】
:
: 这公司也不好说，等老头下台了照样外包，烙印药原料又便宜又好。
| T**********e
发帖数: 29576 | 5
烙印造药因为不管专利已经成气候了，大小化工厂遍地，米国因为国际战略还不能搞他
，无解。
【在 r*********t 的大作中提到】
: 就看国民能否在4年内醒来。没醒过来，还相信和党和主党唱双簧，还去订阅这些左媒
: ，那么就会发生你说的。
|
|
